Key result
Non-immunogenic staphylokinase linked to reduced thrombotic lesions and improved hemodynamics without major bleeding.
Why the study?
The efficacy and safety of non-immunogenic staphylokinase for high-risk massive pulmonary embolism in the early postoperative period were not established.
Does non-immunogenic staphylokinase improve outcomes and maintain safety in a patient with high-risk massive PE in the early postoperative period?
Case Report (n=1)
Does non-immunogenic staphylokinase improve outcomes and maintain safety in a patient with high-risk massive PE in the early postoperative period?
Non-immunogenic staphylokinase may be an effective and safe thrombolytic option for high-risk massive pulmonary embolism even in the early postoperative period.
Repeat non-immunogenic staphylokinase may improve RV function in postoperative massive PE; hypothesis-generating and should not change practice.
A case report of double thrombolytic therapy with non-immunogenic staphylokinase at a dose of 15 mg bolus over 15 s in a patient with a high-risk massive pulmonary embolism (PE) in the early postoperative period due to femoral wound is described. After the second thrombolysis, a decrease in the pulmonary arteries thrombotic lesions according to multislice computed tomography data, restoration of right ventricular function, and a decrease in pulmonary hypertension were observed. Reuse of the non-immunogenic staphylokinase did not lead to the major bleeding and hemorrhagic stroke, did not provoke a drop in hemoglobin and did not require blood transfusion. Upon discharge of the patient, normalization of the general blood test parameters was noted: the level of hemoglobin increased from 86 to 112 g/l, erythrocytes — from 2.8 to 3.5x1012/l, hematocrit — from 26 to 32%. Thus, non-immunogenic staphylokinase has demonstrated high efficacy and safety in the treatment of patient with a high-risk massive PE in the early postoperative period.
No takes yet. Share an insight, caveat, or question.
Konstantinov et al. (2023) conducted a case report in High-risk massive pulmonary embolism (n=1). Non-immunogenic staphylokinase was evaluated. Non-immunogenic staphylokinase safely reduced thrombotic lesions and improved hemodynamics without major bleeding, with hemoglobin increasing from 86 to 112 g/l upon discharge.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: